FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
暂无分享，去创建一个
R. Motzer | T. Choueiri | W. Miller | Chung-Han Lee | H. Kluger | M. Carducci | T. Kuzel | B. Escudier | S. Hotte | P. Bhagavatheeswaran | S. Tykodi | S. George | G. Procopio | H. Desilva | Suresh Nair | Chung-Wei Lee | V. Castonguay | E. Folefac | R. Perets | S. S. Saggi